Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention 

Rhea-AI Summary

Jyong Biotech (NASDAQ:MENS), a Taiwan-based biotechnology company, marked two significant milestones: its Nasdaq IPO bell ringing ceremony on July 2, 2025, and participation in the BIO 2025 International Convention from June 16-19 in Boston.

The company showcased its flagship product MCS®-2, targeting the benign prostatic hyperplasia (BPH) market, which is projected to grow from $4.1 billion in 2020 to $9.8 billion by 2026. Jyong Biotech specializes in plant-derived drugs for urinary system diseases, focusing on the U.S., EU, and Asian markets.

The company plans to expand MCS®-2's market penetration through regional licensing partnerships while pursuing research and development in the urology sector.

News Market Reaction

-8.55%

7 alerts

-8.55% News Effect

+16.8% Peak Tracked

-3.0% Trough Tracked

-$85M Valuation Impact

$911M Market Cap

0.2x Rel. Volume

On the day this news was published, MENS declined 8.55%, reflecting a notable negative market reaction. Argus tracked a peak move of +16.8% during that session. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $85M from the company's valuation, bringing the market cap to $911M at that time.

Data tracked by StockTitan Argus on the day of publication.

New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.

During the BIO 2025 exhibition in Boston, USA, from June 16 to 19, 2025, Jyong Biotech shared and exchanged views about its flagship product, MCS^®-2, with other pharmaceutical players from the U.S., EU, Canada, Mexico, Japan, South Korea, China, and the Middle East. The drug targets the benign prostatic hyperplasia (BPH) market, driven by global aging and escalating obesity rates, with market size projections soaring from $4.1 billion in 2020 to $9.8 billion by 2026, underscoring the pressing need for safe therapeutic solutions.

The Company’s Chairwoman, Fu-Feng Kuo, rang the Company's NASDAQ listing bell on July 2 at the Nasdaq Stock Exchange, signifying a pivotal moment for Jyong Biotech in accessing the global capital market. Jyong Biotech believes that this strategic listing positions the Company to leverage its safety differentiators in plant-based new drugs to capture opportunities in the BPH, lower urinary tract symptoms (LUTS), and prostate cancer prevention sectors, traditionally dominated by synthetic drugs.

The Company aims to maximize MCS^®-2 market penetration in key regions such as the U.S., Europe, and Asia through regional licensing partnerships while simultaneously exploring opportunities in emerging markets. Leveraging the Nasdaq platform, Jyong Biotech is executing a dual-track approach, prioritizing global licensing and sales network expansion for MCS^®-2 alongside research and development in the urology sector to establish a comprehensive matrix of plant-based new drug offerings.

The Company’s Chairwoman, Fu-Feng Kuo, commented: "We believe that from the international resonance of BIO 2025 to the completion of our IPO and the listing of our shares on Nasdaq, Jyong Biotech is poised for global prominence. Anchored in clinical evidence, we are committed to meeting the urgent demand for safe medications in an aging society, setting a new standard for plant-based new drug innovation on a global scale."

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd.is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, MCS^®-2, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email: services@wealthfsllc.com
Phone:+1 628 283 9214

FAQ

When did Jyong Biotech (MENS) ring the Nasdaq bell?

Jyong Biotech rang the Nasdaq bell on July 2, 2025, marking its IPO and entry into the global capital market.

What is the market size projection for BPH treatment that Jyong Biotech's MCS®-2 targets?

The benign prostatic hyperplasia (BPH) market is projected to grow from $4.1 billion in 2020 to $9.8 billion by 2026.

What is Jyong Biotech's (MENS) main product and target market?

Jyong Biotech's flagship product is MCS®-2, a plant-derived drug targeting benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in the U.S., EU, and Asian markets.

Where and when did Jyong Biotech participate in the BIO 2025 Convention?

Jyong Biotech participated in the BIO 2025 International Convention in Boston, USA, from June 16 to 19, 2025.

What is Jyong Biotech's (MENS) business expansion strategy?

Jyong Biotech plans to expand through regional licensing partnerships for MCS®-2 while simultaneously developing additional plant-based drugs in the urology sector.